ドーパミントランスポーターのX線構造は,抗うつ薬のメカニズムを明らかにする
Aravind Penmatsa1, Kevin H Wang, Eric Gouaux
11] Vollum Institute, Oregon Health & Science University, 3181 South West Sam Jackson Park Road, Portland, Oregon 97239, USA [2].
Nature
|September 17, 2013
まとめ
研究者らは,トライサイクル抗うつ剤であるノートリプチリンと結合するドーパミントランスポーターの結晶構造を明らかにした. この構造は,抗うつ薬が神経伝達物質の吸収を阻害する方法を説明し,真核伝達体のユニークな特徴を明らかにします.
科学分野:
- 構造生物学 構造生物学とは
- 神経科学は神経科学である.
- 薬理学 薬理学とは
背景:
- ナトリウム/塩化物結合神経伝達物質のトランスポーターを標的とする抗うつ薬は,うつ病や神経疾患の痛みの治療に不可欠です.
- これらのトランスポーター阻害剤の正確な分子機構は,まだ十分に理解されていません.
研究 の 目的:
- 抗うつ薬と神経伝達物質のトランスポーター間の分子相互作用を解明する.
- ドーパミントランスポーターに対するトリサイクル抗うつ剤の作用の構造的基礎を決定する.
主な方法:
- X線結晶学を用いて,ドロソフィラ・メラノガスタードーパミントランスポーターの構造を決定した.
- 構造は,抗うつ薬ノートリプチリンとの複合で3.0 Åの解像度で解消されました.
主要な成果:
- ドーパミントランスポーターは外側に開いた形状で観察され,ノートリプチリンは基質結合を遮断し,イソメリゼーションを防止しました.
- プロカリオット類 (例えば,LeuT) からの重要な構造的差異が特定され,歪んだヘリックス12とコレステロール分子の相互作用を含む.
- この構造は,ノートリプチリンが,外側に開いた状態を安定させることで,トランスポーター機能を抑制する方法を明らかにしています.
結論:
- この研究は,ナトリウム結合神経伝達物質シンポーターに対する抗うつ薬の作用の分子的理解を提供します.
- コレステロールによる脂質調節を含む,真核のトランスポーター構造に関する新しい洞察が明らかにされました.
- この研究は,化学シナプスにおける神経伝達物質の吸収調節に関する理解を深める.
さらに関連する動画
06:18Brain Slice Biotinylation: An Ex Vivo Approach to Measure Region-specific Plasma Membrane Protein Trafficking in Adult Neurons
Published on: April 3, 2014
12:21Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
関連する概念動画
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...